News
PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Recruitment Progressing as Planned with Over 300 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site...
PolyPid to Present at the Investor Summit Virtual Conference on August 18, 2021
PETACH TIKVA, Israel, Aug. 09, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that Executive Vice President and Chief...
PolyPid to Report Second Quarter 2021 Financial Results and Operational Highlights on August 11, 2021
PETAH TIKVA, Israel, July 28, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its second quarter 2021...
PolyPid Strengthens Executive Team, Appointing Dr. Anthony Senagore as Senior Medical Director
PETAH TIKVA, Israel, July 12, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, today announced that it has appointed leading...
PolyPid Presents today at The Raymond James Human Health Innovation Conference
Presentation led by PolyPid EVP & CFO is taking place today on June 23, 2021 at 9:20am EDTPETAH TIKVA, Israel, June 23, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered,...
PolyPid to Present at Upcoming Healthcare Investor Conferences
PETAH TIKVA, Israel, June 02, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that members of its executive management team...
PolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX Development Program
FDA Agreed that a Single Pivotal Phase 3 Study is Sufficient for Potential Approval of D-PLEX100 for the Prevention of Surgical Site Infections in Colorectal Surgery. Enrollment in Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery Continues to Advance; Over 200...
PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update
Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Surgery Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks Manufacturing Facility Now Fully Scaled Up and Capable of Supporting...
PolyPid to Report First Quarter 2021 Financial Results and Operational Highlights on May 12, 2021
PETAH TIKVA, Israel, April 29, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will report its first quarter 2021...
PolyPid to Participate in Upcoming Investor Conferences
PETAH TIKVA, Israel, Feb. 23, 2021 -- PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics, today announced that it will present at the Raymond...